Barclays PLC increased its holdings in AVITA Medical, Inc. (NASDAQ:RCEL - Free Report) by 340.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,503 shares of the company's stock after purchasing an additional 28,979 shares during the quarter. Barclays PLC owned 0.14% of AVITA Medical worth $402,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also added to or reduced their stakes in RCEL. Essex Investment Management Co. LLC purchased a new position in shares of AVITA Medical in the third quarter worth about $2,477,000. Jane Street Group LLC grew its position in AVITA Medical by 32.7% during the 3rd quarter. Jane Street Group LLC now owns 89,395 shares of the company's stock worth $958,000 after acquiring an additional 22,032 shares during the last quarter. State Street Corp increased its stake in AVITA Medical by 2.4% in the 3rd quarter. State Street Corp now owns 519,997 shares of the company's stock worth $5,574,000 after purchasing an additional 11,997 shares during the period. The Manufacturers Life Insurance Company bought a new stake in AVITA Medical in the second quarter valued at approximately $86,000. Finally, Geode Capital Management LLC boosted its stake in shares of AVITA Medical by 1.4% during the third quarter. Geode Capital Management LLC now owns 594,436 shares of the company's stock valued at $6,373,000 after purchasing an additional 8,361 shares during the period. 27.66% of the stock is owned by institutional investors.
AVITA Medical Trading Up 1.3 %
Shares of RCEL traded up $0.11 during trading hours on Friday, reaching $8.65. 178,976 shares of the company traded hands, compared to its average volume of 181,736. AVITA Medical, Inc. has a 12 month low of $7.51 and a 12 month high of $18.93. The company has a quick ratio of 3.37, a current ratio of 3.73 and a debt-to-equity ratio of 3.48. The company's fifty day moving average price is $12.18 and its two-hundred day moving average price is $10.66. The company has a market capitalization of $226.80 million, a price-to-earnings ratio of -3.88 and a beta of 1.58.
AVITA Medical (NASDAQ:RCEL - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.21). AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. The firm had revenue of $19.55 million for the quarter, compared to the consensus estimate of $19.65 million. During the same period in the previous year, the firm posted ($0.34) earnings per share. Equities research analysts predict that AVITA Medical, Inc. will post -2.35 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently commented on RCEL. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of AVITA Medical in a report on Tuesday, December 24th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of AVITA Medical in a research note on Wednesday, January 8th. Lake Street Capital cut their target price on AVITA Medical from $20.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $18.00.
View Our Latest Analysis on RCEL
AVITA Medical Company Profile
(
Free Report)
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
See Also
Before you consider AVITA Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVITA Medical wasn't on the list.
While AVITA Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
